DENVER − The coronary artery stent wars continue apace with the debut of one-year data for the CD34+-eluting Combo stent by Orbusneich of Hong Kong, one of the mainstays of the first day of the 2017 edition of Transcatheter Cardiovascular Therapeutics here in the Mile High City. Noted cardiologist Mitch Krucoff said that while the data from the 50-site study of the Combo stent might not have been overwhelming, the comparator Xience stent outperformed itself for target vessel failure at a year, dinging the study article's comparative numbers.